<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38899432</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Human umbilical cord-derived mesenchymal stem cell transplantation improves the long COVID.</ArticleTitle><Pagination><StartPage>e29757</StartPage><MedlinePgn>e29757</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29757</ELocationID><Abstract><AbstractText>No effective treatments can ameliorate symptoms of long COVID patients. Our study assessed the safety and efficacy of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) in the treatment of long COVID patients. Ten long COVID patients were enrolled and received intravenous infusions of UC-MSCs on Days 0, 7, and 14. Adverse events and clinical symptoms were recorded, and chest-high-resolution CT (HRCT) images and laboratory parameters were analyzed. During UC-MSCs treatment and follow-up, we did not observe serious adverse events, the symptoms of long COVID patients were significantly relieved in a short time, especially sleep difficulty, depression or anxiety, memory issues, and so forth, and the lung lesions were also repaired. The routine laboratory parameters did not exhibit any significant abnormalities following UC-MSCs transplantation (UMSCT). The proportion of regulatory T cells gradually increased, but it was not statistically significant until 12 months. The proportion of naive B cells was elevated, while memory B cells, class-switched B-cells, and nonswitched B-cells decreased at 1 month after infusion. Additionally, we observed a transient elevation in circulating interleukin (IL)-6 after UMSCT, while tumor necrosis factor (TNF)-&#x3b1;, IL-17A, and IL-10 showed no significant changes. The levels of circulating immunoglobulin (Ig) M increased significantly at month 2, while IgA increased significantly at month 6. Furthermore, the SARS-CoV-2 IgG levels remained consistently high in all patients at Month 6, and there was no significant decrease during the subsequent 12-month follow-up. UMSCT was safe and tolerable in long COVID patients. It showed potential in alleviating long COVID symptoms and improving interstitial lung lesions.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yuling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yanni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Siqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Wenfang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chuang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Yangqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan International Scientific and Technological Cooperation Base of Development and Carcinogenesis, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan International Scientific and Technological Cooperation Base of Development and Carcinogenesis, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Guangxiu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan International Scientific and Technological Cooperation Base of Development and Carcinogenesis, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan International Scientific and Technological Cooperation Base of Development and Carcinogenesis, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Lamei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8685-3674</Identifier><AffiliationInfo><Affiliation>National Engineering Research Center of Human Stem cell, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan International Scientific and Technological Cooperation Base of Development and Carcinogenesis, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020SK3016</GrantID><Agency>The Emergency Projects for COVID-19 by the Science and Technology Department of Hunan Province</Agency><Country/></Grant><Grant><GrantID>2023SK2001</GrantID><Agency>The Emergency Projects for COVID-19 by the Science and Technology Department of Hunan Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014470" MajorTopicYN="Y">Umbilical Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B lymphocytes</Keyword><Keyword MajorTopicYN="N">Treg cells</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">lung lesions</Keyword><Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>20</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38899432</ArticleId><ArticleId IdType="doi">10.1002/jmv.29757</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization (WHO). Coronavirus Disease (COVID&#x2010;19) Dashboard. World Health Organization (WHO). https://covid19.who.int/</Citation></Reference><Reference><Citation>WHO. A Clinical Case Definition of Post COVID&#x2010;19 Condition by a Delphi Consensus. WHO. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation></Reference><Reference><Citation>Al&#x2010;Aly Z, Xie Y, Bowe B. High&#x2010;dimensional characterization of post&#x2010;acute sequelae of COVID&#x2010;19. Nature. 2021;594(7862):259&#x2010;264.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146.</Citation></Reference><Reference><Citation>Cai J, Lin K, Zhang H, et al. A one&#x2010;year follow&#x2010;up study of systematic impact of long COVID symptoms among patients post SARS&#x2010;CoV&#x2010;2 omicron variants infection in Shanghai, China. Emerg Microbes Infect. 2023;12(2):2220578.</Citation></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID&#x2010;19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2010;1615.</Citation></Reference><Reference><Citation>Bowe B, Xie Y, Al&#x2010;Aly Z. Postacute sequelae of COVID&#x2010;19 at 2 years. Nature Med. 2023;29(9):2347&#x2010;2357.</Citation></Reference><Reference><Citation>Yong SJ. Long COVID or post&#x2010;COVID&#x2010;19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737&#x2010;754.</Citation></Reference><Reference><Citation>Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post&#x2010;mortem findings in a series of COVID&#x2010;19 cases from northern Italy: a two&#x2010;centre descriptive study. Lancet Infect Dis. 2020;20(10):1135&#x2010;1140.</Citation></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid&#x2010;19. N Engl J Med. 2020;383(2):120&#x2010;128.</Citation></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al. The IL&#x2010;1&#x3b2;, IL&#x2010;6, and TNF cytokine triad is associated with post&#x2010;acute sequelae of COVID&#x2010;19. Cell Rep Med. 2022;3(6):100663.</Citation></Reference><Reference><Citation>Zadeh FH, Wilson DR, Agrawal DK. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch Microbiol Immunol. 2023;7(2):36&#x2010;61.</Citation></Reference><Reference><Citation>Xu E, Xie Y, Al&#x2010;Aly Z. Long&#x2010;term neurologic outcomes of COVID&#x2010;19. Nature Med. 2022;28(11):2406&#x2010;2415.</Citation></Reference><Reference><Citation>Petrenko Y, Vackova I, Kekulova K, et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Sci Rep. 2020;10(1):4290.</Citation></Reference><Reference><Citation>Li M, Chen H, Zhu M. Mesenchymal stem cells for regenerative medicine in central nervous system. Front Neurosci. 2022;16:1068114.</Citation></Reference><Reference><Citation>Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med. 2013;188(2):133&#x2010;140.</Citation></Reference><Reference><Citation>Bao H, Cheng S, Li X, et al. Functional Au nanoparticles for engineering and long&#x2010;term CT imaging tracking of mesenchymal stem cells in idiopathic pulmonary fibrosis treatment. Biomaterials. 2022;288:121731.</Citation></Reference><Reference><Citation>Gentile P, Sterodimas A, Pizzicannella J, Calabrese C, Garcovich S. Research progress on mesenchymal stem cells (MSCs), adipose&#x2010;derived mesenchymal stem cells (AD&#x2010;MSCs), drugs, and vaccines in inhibiting COVID&#x2010;19 disease. Aging Dis. 2020;11(5):1191&#x2010;1201.</Citation></Reference><Reference><Citation>Meng F, Xu R, Wang S, et al. Human umbilical cord&#x2010;derived mesenchymal stem cell therapy in patients with COVID&#x2010;19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172.</Citation></Reference><Reference><Citation>Shi L, Yuan X, Yao W, et al. Human mesenchymal stem cells treatment for severe COVID&#x2010;19: 1&#x2010;year follow&#x2010;up results of a randomized, double&#x2010;blind, placebo&#x2010;controlled trial. EBioMedicine. 2022;75:103789.</Citation></Reference><Reference><Citation>Eastman Q. Study shows businesses selling unapproved stem cell treatments have turned to long COVID. JAMA. 2023;330(24):2326.</Citation></Reference><Reference><Citation>Cheng L, Wang S, Peng C, et al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single&#x2010;arm study. Signal Transduct Target Ther. 2022;7(1):263.</Citation></Reference><Reference><Citation>Lu H, Wang F, Mei H, Wang S, Cheng L. Human adipose mesenchymal stem cells show more efficient angiogenesis promotion on endothelial colony&#x2010;forming cells than umbilical cord and endometrium. Stem Cells Int. 2018;2018:1&#x2010;15.</Citation></Reference><Reference><Citation>Casarini M, Ameglio F, Alemanno L, et al. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am J Respir Crit Care Med. 1999;159(1):143&#x2010;148.</Citation></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604&#x2010;612.</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID&#x2010;19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2010;461.</Citation></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1&#x2010;year outcomes in hospital survivors with COVID&#x2010;19:a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2010;758.</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. RETRACTED: 6&#x2010;month consequences of COVID&#x2010;19 in patients discharged from hospital: a cohort studypdf. Lancet. 2021;397(10270):220&#x2010;232.</Citation></Reference><Reference><Citation>Evans RA, Leavy OC, Richardson M, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1&#x2010;year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761&#x2010;775.</Citation></Reference><Reference><Citation>Vij R, Kim H, Park H, Cheng T, Lotfi D, Chang D. Adipose&#x2010;derived, autologous mesenchymal stem cell therapy for patients with post&#x2010;COVID&#x2010;19 syndrome: an intermediate&#x2010;size expanded access program. Stem Cell Res Ther. 2023;14(1):287.</Citation></Reference><Reference><Citation>Schou TM, Joca S, Wegener G, Bay&#x2010;Richter C. Psychiatric and neuropsychiatric sequelae of COVID&#x2010;19&#x2014;a systematic review. Brain Behav Immun. 2021;97:328&#x2010;348.</Citation></Reference><Reference><Citation>Jia Y, Cao N, Zhai J, et al. HGF mediates clinical&#x2010;grade human umbilical cord&#x2010;derived mesenchymal stem cells improved functional recovery in a senescence&#x2010;accelerated mouse model of Alzheimer's disease. Adv Sci. 2020;7(17):1903809.</Citation></Reference><Reference><Citation>Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Adv Sci. 2021;8(7):2002944.</Citation></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al. 3&#x2010;month, 6&#x2010;month, 9&#x2010;month, and 12&#x2010;month respiratory outcomes in patients following COVID&#x2010;19&#x2010;related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747&#x2010;754.</Citation></Reference><Reference><Citation>Shi L, Huang H, Lu X, et al. Effect of human umbilical cord&#x2010;derived mesenchymal stem cells on lung damage in severe COVID&#x2010;19 patients: a randomized, double&#x2010;blind, placebo&#x2010;controlled phase 2 trial. Signal Transduct Target Ther. 2021;6(1):58.</Citation></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas&#x2010;Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post&#x2010;acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487&#x2010;e490.</Citation></Reference><Reference><Citation>Oh S&#x2010;J, Lee E&#x2010;N, Park J&#x2010;H, et al. Anti&#x2010;viral activities of umbilical cord mesenchymal stem cell&#x2010;derived small extracellular vesicles against human respiratory viruses. Front Cell Infect Microbiol. 2022;12:850744.</Citation></Reference><Reference><Citation>Qian X, Xu C, Fang S, et al. Exosomal microRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection. Stem Cells Transl Med. 2016;5(9):1190&#x2010;1203.</Citation></Reference><Reference><Citation>Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metab. 2023;34(6):321&#x2010;344.</Citation></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID/post&#x2010;acute sequelae of COVID&#x2010;19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.</Citation></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nature Immunol. 2022;23(2):210&#x2010;216.</Citation></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623:139&#x2010;148. https://doi.org/10.1038/s41586-023-06651-y</Citation></Reference><Reference><Citation>Newell KL, Clemmer DC, Cox JB, et al. Switched and unswitched memory B cells detected during SARS&#x2010;CoV&#x2010;2 convalescence correlate with limited symptom duration. PLoS One. 2021;16(1):e0244855.</Citation></Reference><Reference><Citation>Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423&#x2010;431.</Citation></Reference><Reference><Citation>Agrawal M, Rasiah PK, Bajwa A, Rajasingh J, Gangaraju R. Mesenchymal stem cell induced Foxp3(+) tregs suppress effector T cells and protect against retinal ischemic injury. Cells. 2021;10(11):3006.</Citation></Reference><Reference><Citation>Peng Y, Chen X, Liu Q, et al. Alteration of na&#xef;ve and memory B&#x2010;cell subset in chronic graft&#x2010;versus&#x2010;host disease patients after treatment with mesenchymal stromal cells. Stem Cells Transl Med. 2014;3(9):1023&#x2010;1031.</Citation></Reference><Reference><Citation>Tabera S, Perez&#x2010;Simon JA, Diez&#x2010;Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B&#x2010;lymphocytes. Haematologica. 2008;93(9):1301&#x2010;1309.</Citation></Reference><Reference><Citation>Zhu R, Yan T, Feng Y, et al. Mesenchymal stem cell treatment improves outcome of COVID&#x2010;19 patients via multiple immunomodulatory mechanisms. Cell Res. 2021;31(12):1244&#x2010;1262.</Citation></Reference><Reference><Citation>Deng ZB, Cheng F, Zhang Y. Dynamics of specific antibodies in COVID&#x2010;19 patients after recovery. Epidemiol Infect. 2022;150:e70.</Citation></Reference><Reference><Citation>Traggiai E, Volpi S, Schena F, et al. Bone marrow&#x2010;derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells. 2008;26(2):562&#x2010;569.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>